Roberts Jonathan C, von Drygalski Annette, Zhou Jenny Y, Rodgers George M, Ansteatt Kristin, Tarantino Michael D
Bleeding & Clotting Disorders Institute, University of Illinois College of Medicine - Peoria, Peoria, IL, USA.
Hemophilia and Thrombosis Treatment Center, University of California at San Diego, San Diego, CA, USA.
J Blood Med. 2022 Oct 21;13:611-618. doi: 10.2147/JBM.S365996. eCollection 2022.
Hereditary antithrombin deficiency (ATD) is a rare autosomal dominant condition (estimated prevalence 1:500-1:5000). Most ATD patients have AT activity levels 40-60% of normal. We present treatments for venous thromboembolism (VTE) in five cases of hereditary ATD. Four patients had a family history of ATD, and one had a mutation. The majority of patients had a VTE while on prophylactic anticoagulation. AT concentrate augmentation was added in these cases to treat the VTE and for prophylaxis against further episodes. Two patients had significant bleeding events, one had permanent physical sequelae. Two of the patients were pregnant. VTE is a common cause of morbidity and mortality during pregnancy. Although low molecular weight heparins are the drugs of choice during pregnancy, this treatment was inadequate in one patient (developed VTE on therapy). These cases emphasize the need to screen for ATD in young patients (<55 years) presenting with VTE. AT augmentation therapy may be necessary in patients inadequately treated with conventional anticoagulants. Careful monitoring and individualized care are needed in ATD patients, especially those with demonstrated bleeding tendencies.
遗传性抗凝血酶缺乏症(ATD)是一种罕见的常染色体显性疾病(估计患病率为1:500 - 1:5000)。大多数ATD患者的抗凝血酶活性水平为正常水平的40% - 60%。我们介绍了5例遗传性ATD患者静脉血栓栓塞症(VTE)的治疗情况。4例患者有ATD家族史,1例有基因突变。大多数患者在接受预防性抗凝治疗时发生了VTE。在这些病例中加用了抗凝血酶浓缩剂来治疗VTE并预防进一步发作。2例患者发生了严重出血事件,1例有永久性身体后遗症。2例患者为孕妇。VTE是孕期发病和死亡的常见原因。虽然低分子肝素是孕期的首选药物,但1例患者(在治疗期间发生VTE)使用这种治疗方法并不充分。这些病例强调了对出现VTE的年轻患者(<55岁)进行ATD筛查的必要性。对于使用传统抗凝剂治疗效果不佳的患者,可能需要进行抗凝血酶增强治疗。对ATD患者,尤其是那些有出血倾向的患者,需要进行仔细监测和个体化护理。